Health & Environmental Research Online (HERO)


Print Feedback Export to File
1508641 
Journal Article 
Osteoresorptive arsenic intoxication 
Dani, SU 
2013 
Yes 
Bone
ISSN: 8756-3282
EISSN: 1873-2763 
53 
541-545 
English 
A 47-year-old woman consulted her dermatologist complaining whole body dermatitis, urticaria and irritating bullous eruptions on the plantar and side surfaces of her feet. She had had multiple hypopigmented spots on her skin since her early adulthood. The patient was treated with topical medication without significant improvement of symptoms. One year later she suffered a myocardial infarction, accompanied by refractory anaemia. At the age of 49, a breast cancer was diagnosed and shortly thereafter her last menstruation occurred. At age 50years, upon complaint of weight loss despite normal food intake, Hashimoto thyroiditis with latent hyperthyroidism, vitamin D insufficiency with secondary hyperparathyroidism, and poikilocytic anaemia with anisochromia, hypochromia, anisocytosis, elliptocytes, drepanocytes, dacryocytes, acanthocytes, echinocytes, schizocytes, stomatocytes and target cells were diagnosed. The osteodensitometric and laboratory examinations revealed osteoporosis with sustained elevation of urinary Dipyridinolin-crosslinks (u-Dpd), and urinary arsenic (u-As) of 500μg/l (equivalent to 0.5 parts per million-ppm, 2.5μg/mg creatinine/dl, u-As: Phosphate of 26μg/mmol; the estimated bone As:P and As/kg body weight were 500μg/g and 11.3mg/kg, respectively). Thalassemia, immunoglobinopathy and iron deficiency were excluded. Supplementation with oral vitamin D and calcium, and antiresorptive therapy with intravenous zolendronate normalised the u-Dpd, significantly decreased the urinary arsenic concentration, and cured the anemia and the urticaria. A diagnosis of osteoresorptive arsenic intoxication (ORAI) was established. 
Arsenic; Phosphorus; As:P ratio; Bone resorption; Osteoporosis 
IRIS
• Arsenic (Inorganic)
     1. Literature
          Lit search updates through Oct 2015
     3. Hazard ID Screening
          Other potentially supporting studies
• Arsenic Susceptibility
     Life Stages Citation Mapping
          Top 5%
• Inorganic Arsenic (7440-38-2) [Final 2025]
          PubMed
          Considered New
          WOS
          PubMed
          Considered New
          PubMed
          Considered New
          ToxNet
          Considered New
          ToxNet
          Excluded
               Toxnet Duplicates
          ToxNet
          Excluded
               Toxnet Duplicates
          ToxNet
          Excluded
               Toxnet Duplicates
     2. Lit Search Updates through Oct 2015
          PubMed
          WOS
          ToxNet
          Considered
          Not Relevant